StockDriftsStockDriftsTop 6 Foresite Capital Management IV LLC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| PHVS | Pharvaris N.V. | 56.95% | 4.78M | $165.2M | +0.00%(+0) | $24.90(+41.12%) | 2026-06-30 | |
| CYTK | CYTOKINETICS INC | 20.98% | 714.7K | $60.9M | +42.00%(+211.40K) | $54.20(+36.77%) | 2026-06-30 | |
| EIKN | Eikon Therapeutics, Inc. | 8.74% | 1.94M | $25.4M | +0.00%(+0) | $10.58(+4.44%) | 2026-06-30 | |
| RLAY | Relay Therapeutics, Inc. | 8.06% | 1.25M | $23.4M | +25.00%(+250.00K) | $8.25(+140.84%) | 2026-06-30 | |
| XENE | Xenon Pharmaceuticals Inc. | 3.33% | 160.0K | $9.7M | +0.00%(+0) | $32.78(+90.21%) | 2026-06-30 | |
| CRNX | Crinetics Pharmaceuticals, Inc. | 1.93% | 150.0K | $5.6M | new | $35.84(+136.30%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | +11.80% | +39.75% | -16.60% | -59.64% |
| Top 20 Holdings Unweighted | +8.08% | +26.25% | -11.89% | -46.91% |
Foresite Capital Management IV LLC reports $290.15M in US-listed equity holdings across 6 positions in its most recent 13F filing. Its largest disclosed positions are PHVS (57.0%), CYTK (21.0%) and EIKN (8.7%). The top 20 holdings account for 99.99% of reported assets. Its disclosed equity book has returned +39.75% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Foresite Capital Management IV LLC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Foresite Capital Management IV LLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1704132). View Foresite Capital Management IV LLC’s 13F filings on SEC